SEC Form 4 · accession 0001250853-16-000152
LIXTE BIOTECHNOLOGY HOLDINGS, INC. · NMAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen J. Forman
Director
Period of report
May 13, 2016
Accepted (ET)
Jun 7, 2016 · 2:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001335105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $0.16 | May 13, 2016 | A | 200,000 | A | — | May 13, 2021 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1The option vests as to 100,000 shares on May 13, 2016 and 100,000 shares on May 13, 2017.